Faculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC, V6T 1Z3, Canada.
Department of Medicine, Institute for Heart and Lung Health, University of British Columbia, Vancouver, Canada.
BMC Pulm Med. 2018 Feb 12;18(1):33. doi: 10.1186/s12890-018-0598-4.
Understanding factors associated with the inappropriate or excessive use of short-acting beta agonists (SABA) can help develop better policies.
We used British Columbian (BC)'s administrative health data (1997-2014) to create a retrospective cohort of asthma patients aged between 14 and 55 years. The primary and secondary outcomes were, respectively, inappropriate and excessive use of SABA based on a previously validated definition. Exposures were categorised into groups comprising socio-demographic variables, indicators of type and quality of asthma care, and burden of comorbid conditions.
343,520 individuals (56.3% female, average age 30.5) satisfied the asthma case definition, contributing 2.6 million person-years. 7.3% of person-years were categorised as inappropriate SABA use and 0.9% as excessive use. Several factors were associated with lower likelihood of inappropriate use, including female sex, higher socio-economic status, higher continuity of care, having received pulmonary function test in the previous year, visited a specialist in the previous year, and the use of inhaled corticosteroids in the previous year. An asthma-related outpatient visit to a general practitioner in the previous year was associated with a higher likelihood of inappropriate SABA use. Similar associations were found for excessive SABA use with the exception that visit to respirologist and the use of systemic corticosteroids were associated with increased likelihood of excessive use.
Despite proven safety issues, inappropriate SABA use is still prevalent. Several factors belonging to patients' characteristics and type/quality of care were associated with inappropriate use of SABAs and can be used to risk-stratify patients for targeted attempts to reduce this preventable cause of adverse asthma outcomes.
了解与短效 β 激动剂(SABA)不适当或过度使用相关的因素有助于制定更好的政策。
我们使用不列颠哥伦比亚省(BC)的行政健康数据(1997-2014 年)创建了一个年龄在 14 至 55 岁之间的哮喘患者回顾性队列。主要和次要结局分别是基于先前验证的定义,SABA 的不适当和过度使用。暴露分为包含社会人口统计学变量、哮喘护理类型和质量指标以及合并症负担的组。
343,520 人(56.3%女性,平均年龄 30.5 岁)符合哮喘病例定义,贡献了 260 万人年。7.3%的人年被归类为不适当的 SABA 使用,0.9%为过度使用。一些因素与不适当使用的可能性降低相关,包括女性、较高的社会经济地位、较高的护理连续性、在前一年进行了肺功能测试、在前一年就诊过专家以及在前一年使用了吸入皮质类固醇。在前一年接受全科医生的哮喘相关门诊就诊与不适当的 SABA 使用可能性增加相关。对于过度使用 SABA 也发现了类似的关联,除了就诊于呼吸科医生和使用全身皮质类固醇与过度使用的可能性增加相关。
尽管存在已证实的安全性问题,但不适当的 SABA 使用仍然普遍存在。属于患者特征和护理类型/质量的几个因素与 SABAs 的不适当使用相关,可以用于对患者进行风险分层,以便有针对性地尝试减少这种可预防的不良哮喘结局的发生。